Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

By F. Kabbinavar, H. Hurwitz, L. Fehrenbacher, N. Meropol, W. Novotny, G. Liebérman, S. Griffing, E. Bergsland. Journal of Clinical Oncology, 2003

1,740 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/2df267053f1280b807c5711633d7e87a2f139400

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Rakesh K. Jain
2. N. Ferrara
3. A. Adamis
4. H. Gerber
5. D. Duda
6. W. Novotny
7. Kenneth J. Hillan
8. D. McDonald

In Oncology

1. N. Ferrara
2. Rakesh K. Jain
3. A. Adamis
4. D. McDonald
5. D. Duda
6. H. Gerber
7. Jay S. Loeffler
8. W. Novotny

Citations in the corpus

• Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. (2008, result): “In these studies, TTP or PFS ranged from 9 to 11 months, representing an increase in disease-free survival of approximately 4 months with the addition of bevacizumab.(3,4,9,10) The TREE-2 results are also consistent with the Eastern Cooperative Oncology Group E3200 study in which the addition of bev”
• Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. (2005, background): “In particular, targeted therapies, such as two monoclonal antibodies directed against epidermal growth factor receptors or vascular endothelial growth factor (cetuximab and bevacizumab, respectively), showed antitumor activity alone and in combination with chemotherapy in advanced CRC.(30,31) Phase ”
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer (2006, background): “For example, the efficacy and toxicity of bevacizumab with chemotherapy were not always dose-dependent”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, background): “There is no clear evidence supporting the optimal dose in this situation (5 or 10 mg/kg) [44, 49].”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…in metastatic prostate cancer, relapsed metastatic breast cancer and metastatic renal cell carcinoma show clinical benefit of blocking VEGFA 82 , 270 • Bevacizumab combined with chemotherapy produces clinical benefit in metastatic colorectal cancer 78 Development of ranibizumab 18 for use in the eye”
• The biology of VEGF and its receptors (2003, background): “Phase 2 clinical data have provided initial evidence that rhuMab VEGF, in combination with conventional chemotherapy, results in increase in time to progression and even survival in patients with metastatic colorectal carcinom”
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. (2007, result): “Because that study was neither designed nor powered to provide a definitive dose comparison, we concluded from a review of its findings that a dose of 10 mg/kg is active when combined with chemotherapy.(11) Although the present study’s results prove that assumption to be correct, they do not provide”
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004, background): “The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.”